Кандид-В6

Quick links

Choose a section

Quick links to important sections

Advertisements

Кандид-В6

Selected form

Advertisements
Advertisements
Advertisements

Overview of Кандид-В6

Quick Facts

Property Description
Active ingredient Clotrimazole
Form Vaginal tablets, vaginal cream
Pharmacological class Azole Antifungal / Imidazole Derivative
Common purpose To suppress fungal growth
Origin Synthetic compound

Definition and Pharmacological Class

Candid-B6 is a synthetic broad-spectrum antifungal medication that belongs to the azole class of antifungals, specifically the imidazole derivatives. Its single active ingredient (INN) is Clotrimazole, a compound utilized to treat infections caused by susceptible fungi and yeasts.

Composition, Dosage Forms, and General Action Principle

The active component, Clotrimazole, is a monopreparation (single-ingredient product) within Candid-B6, manufactured by Glenmark Pharmaceuticals Ltd. This medication is typically manufactured for local administration in the form of vaginal tablets or a vaginal cream. These localized dosage forms allow for the targeted, topical delivery of the active substance directly to the site of infection, minimizing systemic exposure. The general purpose of Candid-B6 is to suppress the growth and activity of pathogenic fungi. Clotrimazole achieves this by inhibiting the synthesis of ergosterol, a vital component of the fungal cell membrane, which ultimately leads to the disruption of the organism's structure and function. This mechanism is widely accepted for eliminating the source of fungal infections, such as vaginal candidiasis.

Advertisements

What side effects are possible with Кандид-В6?

Possible side effects and safety information

Regulatory documents classify the adverse reactions associated with clotrimazole vaginal products based on their frequency and the body system affected. Since the active ingredient is administered locally as a vaginal cream or tablet, systemic absorption is low, leading to a safety profile characterized primarily by localized reactions.


Frequency-Classified Adverse Reactions

The most frequent effects are generally classified as Common and are confined to the application site. These include vulvovaginal burning, itching, or irritation. Less frequent, or Uncommon, reactions may include rash or abdominal pain. Rare reactions documented in official regulatory sources include serious hypersensitivity responses, such as anaphylactic reactions, syncope (fainting), or angioedema.

System-Organ Class Examples of Documented Effects
Reproductive System Vulvovaginal discomfort, burning, pelvic pain
Immune System Hypersensitivity, Anaphylactic reaction (Rare)
Gastrointestinal Abdominal pain (Uncommon)

Safety Considerations and Restrictions

Safety profiles note that localized reactions may be more pronounced at the start of treatment. A specific restriction documented in official labeling is the potential for the product to reduce the effectiveness of non-latex barrier contraceptive methods, such as condoms or diaphragms, due to interaction with the formulation's excipients. Furthermore, the product is contraindicated for use in individuals with known hypersensitivity to clotrimazole or any other component in the formulation.

While use during the first trimester of pregnancy is generally advised to be avoided, official safety notes state that use in later stages must be preceded by a professional benefit-risk assessment. The safety profile does not list specific adjustments for individuals based on age or renal/hepatic impairment for this topical formulation.

Advertisements

Overdose and Emergency Response

The official regulatory documents for Candid-В6 (Clotrimazole, vaginal formulation) clearly state that systemic intoxication is highly unlikely. This determination is based on the minimal systemic absorption of the active ingredient when administered via the topical route. As a result, no severe or life-threatening systemic outcomes, such as cardiovascular or neurological toxicity, are formally documented in the official overdose sections of the regulatory labels.

The only overdose scenario addressed in official labeling is the accidental oral ingestion of large quantities of the product. In this low-risk event, the documented manifestations are non-specific gastrointestinal disturbances, including nausea, vomiting, or diarrhea.

For any accidental oral ingestion, the mandated action is to seek immediate medical attention or contact a poison control center. Management is restricted entirely to symptomatic and supportive treatment, as no specific antidote is known for the active substance. Furthermore, official documentation states that hospital monitoring may be required solely for observation following significant accidental oral intake, confirming the regulatory approach is focused on supportive care and cautious observation. The overdose profile carries no population-specific considerations in the official regulatory documentation.

Advertisements

Therapeutic Uses of Кандид-В6

What Кандид-В6 Treats — Main Uses and Benefits

The active ingredient in Candid-B6 is commonly used to help with conditions involving vaginal yeast infections (vulvovaginal candidiasis). This treatment is relevant in contexts marked by increased discomfort or tension stemming from the localized fungal overgrowth, where it is used in situations involving certain distressing symptoms.

Candid-B6 is primarily applied across domains where additional symptomatic support is needed for conditions presenting with acute or disruptive episodes. The medication helps address symptom clusters that may become intense or disruptive, including itching (pruritus), burning sensations, and abnormal vaginal discharge. It is often used when symptoms intensify and supportive relief is needed, such as following antibiotic therapy. The general benefit is that it supports the patient during difficult episodes by easing distress.

“The treatment plays a role in managing conditions where symptoms may intensify temporarily, providing the support that helps ease the overall symptom burden.”

This supportive relief assists with maintaining functional stability and contributes to improved day-to-day comfort during symptomatic periods.


Quick Fact: Relief for Localized Discomfort
Primary Indication Conditions involving episodic or fluctuating manifestations (VVC)
Symptom Focus Symptoms related to inflammatory or irritative states (itching, burning)
General Benefit Provides support that helps ease the overall symptom burden
Use Context Applied in clinical settings that involve acute or unstable symptom patterns

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Кандид-В6

The official regulatory documents define eligibility for Clotrimazole vaginal products based on absolute prohibitions, age, clinical history, and physiological status. The unrestricted use is typically limited to adult women aged 16 to 60 with uncomplicated infections.

Absolute Contraindication The medicine is contraindicated in patients with a known hypersensitivity (allergy) to the active substance Clotrimazole, related azole antifungals, or any of the product’s excipients.

Age and Pregnancy Status Status Eligibility Rule
Pediatric Use Not for use in patients under 16 years of age.
Geriatric Use Patients aged over 60 years must seek medical advice prior to use.
Lactation Use is generally permitted during breastfeeding.
Pregnancy Conditional use; preferably avoided in the first trimester and requires medical supervision in later trimesters.

Exclusions from Self-Treatment The regulatory label requires medical advice, defining non-eligibility for self-treatment, if a patient presents with irregular vaginal bleeding, sores or ulcers in the genital area, lower abdominal pain, fever, or a history of more than two infections in the last six months. Treatment should not be performed during the menstrual period.

Advertisements

What should I know about interactions with other medicines?

The active ingredient in Кандид-В6, Clotrimazole, has officially documented interaction patterns detailed within regulatory labeling for the vaginal formulation. These documented interactions fall into two categories: potential pharmacokinetic effects on specific concomitant medicines and material compatibility restrictions involving local substances.

Interaction with Systemic Medicines

Co-administration with specific oral immunosuppressants is addressed in regulatory documents due to the risk of exposure modification. For instance, concomitant use with tacrolimus or sirolimus may result in an increase in the plasma concentrations of these medicines. This pharmacokinetic interaction pattern is attributed to potential inhibition of the Cytochrome P450 (CYP) enzyme system, specifically CYP3A4, which results from minimal systemic absorption. The official regulatory advice for this clinically relevant interaction is that treatment requires close patient monitoring and, if necessary, the determination of respective plasma levels.

Restrictions on Local Substances

The medication may cause material damage to latex contraceptives, including condoms and diaphragms, thereby reducing their barrier efficacy. Therefore, these products are not advised for use during treatment. To avoid interference with the localized action of the drug, the concurrent use of tampons, intravaginal douches, or spermicides is restricted during the period of therapy. No interactions with food, alcohol, or herbal products are explicitly documented in the official prescribing information for this topical dosage form.

Advertisements

Mechanism of Action

Targeted Fungal Enzyme Inhibition

This mechanism describes how the active component, Clotrimazole, acts as an inhibitor of the fungal enzyme lanosterol 14-alpha demethylase. By blocking this enzyme, the drug prevents the formation of ergosterol, which is essential for the fungal cell membrane's structure. The resulting ergosterol depletion and accumulation of toxic sterols cause the cell membrane's integrity to fail, which results in fungal cell death (a fungicidal action).

Coenzyme-Assisted Host Tissue Repair

The second component, Pyridoxine, contributes mechanistically by acting as a precursor to the coenzyme pyridoxal 5-phosphate (PLP). PLP is an indispensable cofactor that supports host metabolic pathways involved in the synthesis of structural proteins and lipids. This action supports the metabolic processes required for mucosal epithelial tissue repair and regeneration.

Advertisements

Dosage and Administration Information

The administration of the active ingredient in Кандид-В6 (Clotrimazole) is limited to the intravaginal route for internal application, with the cream formulation also utilized for external topical application to address associated vulvar irritation. The medication is not intended for oral consumption.

Dosing is organized across fixed-duration regimens. These include a single-day course (500 mg vaginal tablet), a three-day course (200 mg vaginal tablet or 2% cream), or a standard seven-day course (100 mg vaginal tablet or 1% cream). Internal dosage forms are utilized for administration once daily, a timing typically set at bedtime to ensure the preparation remains in place for an optimal duration.

Proper use involves the insertion of the internal forms as high as possible, usually with the supplied applicator. The completion of the full course of the regimen is standard practice. For age-based usage, the product is for adults and children 12 years of age and over; use in children under this age involves professional consultation.

There are specific procedural constraints associated with this treatment. The use of other vaginal products such as tampons, douches, or spermicides is avoided during the treatment period. Furthermore, the active ingredient can damage the material of latex products like condoms and diaphragms, a restriction that applies throughout the period of use.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Кандид-В6

Evidence for use in Acute Vulvovaginal Candidiasis

Research into the active ingredient in Кандид-В6 has primarily relied on short-term Randomized Controlled Trials (RCTs) and systematic reviews and was studied for conditions characterized by fluctuating or episodic manifestations, such as vulvovaginal candidiasis (VVC). These studies monitored the measured status of physical discomfort symptoms, including itching, burning, and discharge, as well as the mycological status (the presence of Candida species) over defined short-term intervals. The research was conducted during periods of increased symptom activity and focused on assessing outcomes related to episodic or acute changes.

Research highlights changes measured during the study period over the short-term follow-up periods, which typically range from 5 to 15 days. The body of evidence for this type of short-term evaluation is generally characterized by a High level of certainty by scientific review bodies. Studies report how symptoms evolved in the observed populations, and the overall body of work contributes to the broader evidence landscape regarding this type of infection.

Despite the volume of research, evidence quality varies across studies, particularly older ones. Researchers have noted heterogeneity in how the definition of a "clinical cure" was applied and measured across different trials. Furthermore, reported outcomes were focused on short-term follow-up durations, meaning existing studies provide limited insight into symptom patterns beyond the immediate post-treatment intermediate-term period.


Evidence for use in Recurrent Vulvovaginal Candidiasis

For conditions presenting with cycles of stability and flare-ups, such as recurrent VVC, research has shifted focus to studies exploring long-term outcomes. The active ingredient was studied for its evaluation in regimens that explored the control of symptomatic recurrence over extended observation periods. The research utilized RCTs and prospective trials with long-term follow-up durations (typically six months to a year). These studies monitored outcomes related to the rate of new symptomatic episodes and the mycological status during the long-term observation periods.

Studies report how symptoms evolved in these populations during prolonged periods of observation, providing context on long-term patterns. However, the overall evidence level for this type of extended evaluation is generally characterized by review bodies as Moderate. Findings varied in the assessment of symptomatic recurrence over time, especially when different treatment approaches were compared in studies.

Key Studies & References

  1. Clotrimazole Vaginal Tablet Label - DailyMed/U.S. National Library of Medicine
  2. Maintenance therapy for recurrent vulvovaginal candidiasis
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Кандид-В6 (FAQ)

Q: How soon can improvement in symptoms be expected after starting treatment?

Studies and official information describe that measured symptom relief may be observed following the start of the regimen. The onset of the full effect monitored in short-term clinical trials typically occurred within the follow-up period, which has been reported to range from 5 to 15 days, depending on the study.

Q: How long is the full course of treatment usually required?

Regulatory guidance focuses on the procedural requirement to complete the fixed treatment schedule. Depending on the specific dosage form, official regimens are described as lasting one, three, or seven days. The completion of the full prescribed course is a requirement described in regulatory documents.

Q: Is there an interaction between Кандид-В6 and alcohol?

According to the official product information for the topical dosage form, no interaction with alcohol consumption is explicitly documented. This is due to the local route of administration of the active ingredient, which results in limited systemic absorption.

Q: Does Кандид-В6 interact with herbal products or supplements?

Official regulatory labeling does not explicitly document any interaction between the active ingredient and herbal products or supplements. This information is consistent with the lack of documented systemic interaction for this localized topical medicine.

Q: Must the full course of treatment be completed, even if symptoms disappear?

Regulatory guidance emphasizes the importance of completing the full course of the fixed treatment regimen. The official documents advise against discontinuing use early, as adherence to the full regimen is a required procedural constraint.

Q: Does Кандид-В6 interact with vitamins?

Official regulatory documentation does not explicitly list interactions between the topical formulation and vitamins. This reflects the product’s local route of administration and generally low systemic absorption.

Q: What are the instructions if a dose of Кандид-В6 is missed?

Patient information leaflets typically contain instructions advising that if a dose is missed, administering it as soon as the user remembers is an option. If it is almost time for the next scheduled dose, the missed dose is usually skipped, following the timing set by the prescribed regimen.

Q: Does Кандид-В6 affect the gut microflora?

Official regulatory documentation related to pharmacokinetics describes the medicine as being applied locally with limited systemic absorption. Therefore, the product information does not describe specific effects on the intestinal or gut microflora.

Q: What do official documents say about use for women in post-menopause (over 60)?

Official eligibility documents define specific age rules for self-treatment. The guidelines state that individuals aged over 60 years are required to seek medical advice prior to starting use.

Q: What should be done if symptoms do not improve after completing the regimen?

Regulatory guidance contained in patient counseling sections describes the requirement to consult a health professional if symptoms persist or if there is no measured improvement after completing the full recommended regimen.

Q: Is headache listed as a documented side effect of the medicine?

Official regulatory labeling classifies adverse reactions based on frequency and system. Headaches are not listed among the frequency-classified adverse reactions documented in official regulatory labeling for this topical dosage form.

Q: How does official labeling define when the medicine is not suitable for self-treatment?

Official labeling defines non-eligibility for self-treatment based on two main categories. These include the documented presence of specific symptoms, such as fever or irregular vaginal bleeding, and a known hypersensitivity (allergy) to the active ingredient or any other component in the formulation.

Q: Is Кандид-В6 used to treat men?

Regulatory documents define the indications for this product as vulvovaginal candidiasis, which focuses the treatment on the vaginal and associated vulvar areas. The official product labeling is centered on this specific patient population.

Q: Is Кандид-В6 intended only for women?

As defined in the regulatory documents, the indications for use focus on treating vulvovaginal candidiasis. This limits the intended application of the vaginal dosage forms to the vaginal and associated vulvar areas in women.

Q: What is the official restriction on the frequency of self-treatment?

Regulatory guidelines restrict self-treatment for frequent or recurring infections. The official documents describe the requirement to seek medical advice prior to initiating treatment if a patient has a history of more than two infections within the last six months.

Q: Which official documents describe the indications for Кандид-В6?

The formal indications for the use of this medicine are formally described in regulatory documents published by governmental authorities. These include resources such as the FDA DailyMed Labeling, the EMA Summary of Product Characteristics (SmPC), and equivalent governmental medicinal product guides.

Q: Does Кандид-В6 affect the ability to become pregnant (fertility)?

Official regulatory documents for the topical dosage form do not describe specific effects on fertility. Information regarding reproductive function is focused on use during pregnancy and lactation.

Q: Is there a special diet required while using Кандид-В6?

Official regulatory labeling does not explicitly document any requirement for patients to follow a special diet during the period of treatment. This is based on the lack of documented interactions with food.

Q: What does the 'B6' in the drug name refer to?

The name incorporates a reference to the second active component, which is Pyridoxine. Pyridoxine is chemically known as Vitamin B6, and its inclusion relates to the descriptive mechanism for supporting host tissue repair.

Q: Is there a risk of resistance developing with frequent use?

Regulatory guidance mandates the completion of the full course and restricts frequent self-treatment. These measures align with established pharmacological principles aimed at maintaining antimicrobial efficacy and preventing the potential for resistance development.

Advertisements

How should Кандид-В6 be stored and disposed of?

Storage and Handling Requirements

Official regulatory labeling dictates that Clotrimazole vaginal products must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with temporary excursions permitted. The product must not be frozen and must be protected from both moisture and excessive heat. To maintain stability, the medication should be stored in its original container and kept tightly closed.

Child Safety and Disposal

As a mandatory safety requirement, the medicine must be stored out of the sight and reach of children.

Regarding disposal of unused or expired product, official instructions advise using a local drug take-back program. If a take-back program is unavailable, the product should be mixed with an undesirable substance and placed in a sealed bag before being discarded in the household trash. The product must not be flushed down a toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Кандид-В6 found in:

A-Z Index: